Company intelligence / Profile preview
AdAlta
Bundoora, Victoria, Australiaadalta.com.au ↗
- Ownership
- Public · 1AD
- Employees
- ~9
- Development stage
- Other
01
Overview
Lead asset AD-214 is in Phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. The company has also developed i-CAR-T cell therapies for solid tumors and i-PET imaging for cancer patients.
- Therapeutic areas
- OtherOphthalmologyOncologyPulmonology
- Modalities
- Protein therapeuticsi-body platformCell-based therapeutics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
GE Healthcare Technologies Inc (for i-body enabled PET imaging agents)Carina Biotech Pty Ltd (for CAR-T cell therapies)
Beyond the preview
Go deeper on AdAlta.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdAlta.